Download PDF
CC BY-NC-ND 4.0 · Indian J Radiol Imaging 2013; 23(04): 354-365
DOI: 10.1055/s-0041-1734382
PET-CT

FDG-PET/CT in lymphoma

Maria M D′souza
Department of PET Imaging, Institute of Nuclear Medicine and Allied Sciences, Brig. SK Majumdar Marg, New Delhi, India
,
Abhinav Jaimini
Department of PET Imaging, Institute of Nuclear Medicine and Allied Sciences, Brig. SK Majumdar Marg, New Delhi, India
,
Abhishek Bansal
Department of PET Imaging, Institute of Nuclear Medicine and Allied Sciences, Brig. SK Majumdar Marg, New Delhi, India
,
Madhavi Tripathi
Department of Nuclear Medicine, AIIMS, New Delhi, India
,
Rajnish Sharma
Department of PET Imaging, Institute of Nuclear Medicine and Allied Sciences, Brig. SK Majumdar Marg, New Delhi, India
,
Anupam Mondal
Department of PET Imaging, Institute of Nuclear Medicine and Allied Sciences, Brig. SK Majumdar Marg, New Delhi, India
,
Rajendra Prashad Tripathi
Department of PET Imaging, Institute of Nuclear Medicine and Allied Sciences, Brig. SK Majumdar Marg, New Delhi, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Lymphomas are a heterogeneous group of diseases that arise from the constituent cells of the immune system or from their precursors. 18F-fludeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) is now the cornerstone of staging procedures in the state-of-the-art management of Hodgkin′s disease and aggressive non-Hodgkin′s lymphoma. It plays an important role in staging, restaging, prognostication, planning appropriate treatment strategies, monitoring therapy, and detecting recurrence. However, its role in indolent lymphomas is still unclear and calls for further investigational trials. The protean PET/CT manifestations of lymphoma necessitate a familiarity with the spectrum of imaging findings to enable accurate diagnosis. A meticulous evaluation of PET/CT findings, an understanding of its role in the management of lymphomas, and knowledge of its limitations are mandatory for the optimal utilization of this technique.

Keywords

Imaging - lymphoma - PET/CT


Publication History

Article published online:
30 July 2021

© 2013. Indian Radiological Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Toma P, Granata C, Rossi A, Garaventa A. Multimodality imaging of Hodgkin Disease and Non-Hodgkin Lymphomas in children. Radiographics 2007;27:1335-54.
  • 2 Hutchings M, Barrington S. PET/CT for therapy response assessment in lymphoma. J Nucl Med 2009;50 (Suppl 1):S21-30.
  • 3 Lu P. Staging and classification of lymphoma. Semin Nucl Med 2005;35:160-4.
  • 4 Küppers R, Engert A, Hansmann ML. Hodgkins lymphoma. J Clin Invest 2012;122:3439-47.
  • 5 Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin′s disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6.
  • 6 Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin 2005;55:368-76.
  • 7 Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: A systematic review. Blood 2008;111:504-16.
  • 8 Vinnicombe SJ, Reznek RH. Computerised tomography in the staging of Hodgkin′s disease and non-Hodgkin′s lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S42-55.
  • 9 Brix G, Lechel U, Glatting G, Ziegler SI, Münzing W, Müller SP, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med 2005;46:608-13.
  • 10 Barentsz J, Takahashi S, Oyen W, Mus R, De Mulder P, Reznek R, et al. Commonly used imaging techniques for diagnosis and staging. J Clin Oncol 2006;24:3234-44.
  • 11 Chawla SC, Federman N, Zhang D, Nagata K, Nuthakki S, McNitt-Gray M, et al. Estimated cumulative radiation dose from PET/CT in children with malignancies: A 5-year retrospective review. Pediatr Radiol 2010;40:681-6.
  • 12 Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, et al. Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology. 1997;203:795-800.
  • 13 Naumann R, Beuthien-Baumann B, Reiss A, Schulze J, Hänel A, Bredow J, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin′s lymphoma. Br J Cancer 2004;90:620-5.
  • 14 Ngeow JY, Quek RH, Ng DC, Tao M, Lim LC, Tan YH, et al. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma. Ann Oncol 2009;20:1543-7.
  • 15 Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A, et al. The usefulness of (18) F-fluorodeoxyglucose positron emission tomography ((18) F-FDG-PET) and a comparison of (18) F-FDG-pet with (67) gallium scintigraphy in the evaluation of lymphoma: Relation to histologic subtypes based on the World Health Organization classification. Cancer 2007;110:652-9.
  • 16 Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio JA, Zhuang H, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003;101:3875-6.
  • 17 Fueger BJ, Yeom K, Czernin J, Sayre JW, Phelps ME, Allen-Auerbach MS. Comparison of CT, PET, and PET/CT for Staging of Patients with Indolent Non-Hodgkin′s Lymphoma. Mol Imaging Biol 2009;11:269-74.
  • 18 Bruzzi JF, Macapinlac H, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, et al. Detection of Richter′s transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 2006;47:1267-73.
  • 19 Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18 fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin′s lymphoma. J Clin Oncol 2005;23:4643-51.
  • 20 Bodet-Milin C, Kraeber-Bodéré F, Moreau P, Campion L, Dupas B, Le Gouill S. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica 2008;93:471-2.
  • 21 Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
  • 22 Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with 18 F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998;19:1055-63.
  • 23 Zinzani PL, Fanti S, Battista G, Tani M, Castellucci P, Stefoni V, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer 2004;91:850-4.
  • 24 Jacobs SA, Vidnovic N, Joyce J, McCook B, Torok F, Avril N. Full-dose 90 Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res 2005;11:7146-50s.
  • 25 Mikhaeel NG, Hutchings M, Fields PA, O′Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514-23.
  • 26 Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin′s disease. J Nucl Med 2002;43:1018-27.
  • 27 Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. 18 F Fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood. 2005;106:1376-81.
  • 28 Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin′s lymphoma and Hodgkin′s lymphoma. Eur J Nucl Med Mol Imaging 2004;31:22-8.
  • 29 Kostakoglu L, Schöder H, Johnson JL, Hall NC, Schwartz LH, Straus DJ, et al. Interim [(18) F] fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: Would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma 2012;53:2143-50.
  • 30 Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med 2000;50 (Suppl 1):S21-30.
  • 31 Delbeke D, Stroobants S, de Kerviler E, Gisselbrecht C, Meignan M, Conti PS. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Oncologist 2009;14:30-40.
  • 32 Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571-8.
  • 33 Metser U, Goor O, Lerman H, Naparstek E, Even-Sapir E. PET-CT of extranodal lymphoma. AJR Am J Roentgenol 2004;182:1579-86.
  • 34 Guermazi A, Brice P, de Kerviler EE, Fermé C, Hennequin C, Meignin V, et al. Extranodal Hodgkin disease: Spectrum of disease. Radiographics 2001;21:161-79.
  • 35 Dodd GD, Greenler DP, Confer SR. Thoracic and abdominal manifestations of lymphoma occurring in the immunocompromised patient. Radiol Clin North Am 1992;30:597-610.
  • 36 Nyberg DA, Jeffrey RB, Federle MP, Bottles K, Abrams DI. AIDS-related lymphomas: Evaluation by abdominal CT. Radiology 1986;159:59-63.
  • 37 Lee WK, Lau EW, Duddalwar VA, Stanley AJ, Ho YY . Abdominal Manifestations of Extranodal Lymphoma: Spectrum of Imaging Findings. AJR Am J Roentgenol 2008;191:198-206.
  • 38 Levine MS, Rubesin SE, Pantongrag-Brown L, Buck JL, Herlinger H. Non-Hodgkin′s lymphoma of the gastrointestinal tract: Radiographic findings. AJR Am J Roentgenol 1997;168:165-72.
  • 39 El-Haddad G, Alavi A, Mavi A, Bural G, Zhuang H. Normal variants in 18F-fluorodeoxyglucose PET imaging. Radiol Clin N Am 2004;42:1063-81.
  • 40 Tatlidil R, Jadavar H, Bading JR, Conti PS. Incidental colonic fluorodeoxyglucose uptaske: Correlation with colonoscopic and histopathologic findings. Radiology 2002;224:783-7.
  • 41 Boellaard R, O′Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: Version 1.0.Eur J Nucl Med Mol Imaging 2010;37:181-200.
  • 42 Lynch MA, Cho KC, Jeffrey RB, Alterman DD, Federle MP. CT of peritoneal lymphomatosis. AJR Am J Roentgenol 1988;151:713-5.
  • 43 Martinez S, Mc Adams HP, Erasmus JJ. Mediastinum. In: Haaga JR, Dogra VS, Forsting M, Gilkeson RC, Ha HK, Sundaram M, editors. CT and MRI of the whole body. 5 th ed. Philadelphia, PA: Mosby Elsevier; 2009. p. 969-1036.
  • 44 Lee KS, Kim Y, Primack SL. Imaging of pulmonary lymphomas. AJR Am J Roentgenol 1997;168:339-45.
  • 45 Strauss LG. Sensitivity and specificity of positron emission tomography (PET) for the diagnosis of lymph node metastasis. Recent Results Cancer Res 2000;157:12-9.
  • 46 Jack CR, O′Neill BP, Banks PM, Reese DF. Central nervous system lymphoma: Histological types and CT appearance. Radiology 1988;167:211-5.
  • 47 Hoffman JM, Waskin HA, Schifter T, Hanson MW, Gray L, Rosenfeld S, et al. FDG-PET in differentiating Lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993;34:567-75.
  • 48 Bragg DG. Lymphoproliferative neoplasms. In: Bragg DG, Rubin P, Hricak H, editors. Oncologic imaging. 2 nd ed. Philadelphia, PA: Saunders; 2002. p. 853-83.
  • 49 Rizvi MA, Evens AM, Tallman MS, Nelson BP, Rosen ST. T-cell non-Hodgkin lymphoma. Blood 2006;107:1255-64.
  • 50 Tsai EY, Taur A, Espinosa L, Quon A, Johnson D, Dick S, et al. Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol 2006;142:577-84.
  • 51 Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18 F-FDG PET/CT 1.0. J Nucl Med 2006;47:885-95.
  • 52 Kumar R, Halanaik D, Malhotra A. Clinical applications of positron emission tomography-computed tomography in oncology. Indian J Cancer 2010;47:100-19.
  • 53 Lustberg MB, Aras O, Meisenberg BR. FDG PET/CT findings in acute adult mononucleosis mimicking malignant lymphoma. Eur J Haematol 2008;81:154-6.
  • 54 Castellucci P, Nanni C, Farsad M, Alinari L, Zinzani P, Stefoni V, et al. Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: Prevalence and scan interpretation. Nucl Med Commun 2005;26:689-94.
  • 55 Perry C, Herishanu Y, Metzer U, Bairey O, Ruchlemer R, Trejo L, et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol 2007;79:205-9.